Table 1.
Demographics and subject characteristics at screening: pharmacodynamics population.
| Parameter | Placebo (n = 12) | Olanzapine (n = 24) | OLZ/SAM (n = 24) |
|---|---|---|---|
| Male, n (%) | 10 (83.3) | 20 (83.3) | 19 (79.2) |
| Age, mean (SD), years | 30.0 (7.2) | 28.0 (4.7) | 28.0 (5.0) |
| Race, n (%) | |||
| White | 7 (58.3) | 20 (83.3) | 10 (41.7) |
| Black or African American | 5 (41.7) | 2 (8.3) | 13 (54.2) |
| American Indian/Alaska native | 0 | 0 | 1 (4.2) |
| Asian | 0 | 1 (4.2) | 0 |
| Multiple races | 0 | 1 (4.2) | 0 |
| Weight, mean (SD), kg | 69.6 (7.0) | 70.7 (7.5) | 71.4 (7.7) |
| Body mass index, mean (SD), kg/m2 | 23.0 (1.9) | 23.2 (1.3) | 23.5 (1.2) |
| Percentage body fat, mean (SD) | 23.5 (10.8) | 24.7 (8.6) | 22.6 (10.8) |
| Fat-free mass,a mean (SD), kg | 53.5 (9.0) | 53.4 (8.8) | 55.3 (9.7) |
| HbA1c, mean (SD), % | 5.2 (0.3) | 5.4 (0.2) | 5.3 (0.2) |
HbA1c hemoglobin A1c, OLZ/SAM combination of olanzapine and samidorphan.
aFat-free mass was measured at the baseline visit.